These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 31205193)

  • 1. Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
    Pozzi M; Carnovale C; Mazhar F; Peeters GGAM; Gentili M; Nobile M; Radice S; Clementi E
    J Clin Psychopharmacol; 2019; 39(4):386-392. PubMed ID: 31205193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
    Stuhec M; Munda B; Svab V; Locatelli I
    J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy.
    Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Qu A; Lee F; Childress A
    J Comp Eff Res; 2024 Sep; 13(9):e240089. PubMed ID: 39132746
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse drug events related to mood and emotion in paediatric patients treated for ADHD: A meta-analysis.
    Pozzi M; Carnovale C; Peeters GGAM; Gentili M; Antoniazzi S; Radice S; Clementi E; Nobile M
    J Affect Disord; 2018 Oct; 238():161-178. PubMed ID: 29883938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.
    Cortese S; Panei P; Arcieri R; Germinario EA; Capuano A; Margari L; Chiarotti F; Curatolo P
    CNS Drugs; 2015; 29(10):865-77. PubMed ID: 26293742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
    PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
    Schein J; Cloutier M; Gauthier-Loiselle M; Catillon M; Xu C; Chan D; Childress A
    J Manag Care Spec Pharm; 2024 Jun; 30(6):528-540. PubMed ID: 38824626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
    Garnock-Jones KP; Keating GM
    Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profiles of methylphenidate, amphetamine, and atomoxetine: analysis of spontaneous reports submitted to the food and drug administration adverse event reporting system.
    Wei W; Chen L; Zhou H; Liu J; Zhang Y; Feng S; Bai Y; Leng Y; Chang E; Huang L
    Front Pharmacol; 2023; 14():1208456. PubMed ID: 37645441
    [No Abstract]   [Full Text] [Related]  

  • 12. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
    Eiland LS; Bell EA; Erramouspe J
    Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.
    Ruggiero S; Rafaniello C; Bravaccio C; Grimaldi G; Granato R; Pascotto A; Sportiello L; Parretta E; Rinaldi B; Panei P; Rossi F; Capuano A
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):415-22. PubMed ID: 23234585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine. Attention-deficit/hyperactivity disorder: no better than methylphenidate.
    Prescrire Int; 2010 Feb; 19(105):5-8. PubMed ID: 20455329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychosis with use of amphetamine drugs, methylphenidate and atomoxetine in adolescent and adults.
    Hamard J; Rousseau V; Durrieu G; Garcia P; Yrondi A; Sommet A; Revet A; Montastruc F
    BMJ Ment Health; 2024 Apr; 27(1):. PubMed ID: 38609318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.
    Barkla XM; McArdle PA; Newbury-Birch D
    BMC Psychiatry; 2015 Oct; 15():270. PubMed ID: 26517983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lisdexamfetamine Dimesylate: A Review in Paediatric ADHD.
    Frampton JE
    Drugs; 2018 Jul; 78(10):1025-1036. PubMed ID: 29923015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
    Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
    Zimovetz EA; Beard SM; Hodgkins P; Bischof M; Mauskopf JA; Setyawan J
    CNS Drugs; 2016 Oct; 30(10):985-96. PubMed ID: 27530525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.